China CRO Sector_Trump's call to reshore drug production hurt market sentiment; China CRO exposure to US commercial projects limited

Trump's call to reshore drug production hurt market sentiment; China CRO exposure to US commercial projects limited Trump's signal to reshore drug production caused market concern China's CRO sector plummeted today as media reported that Trump warned the US pharmaceutical companies to reshore their drug production or face tariffs during a private meeting with several US pharma CEOs on 20 February. Despite the negative impact on sentiment, we do not expect China CROs' revenue and earnings to be meaningfully ...